- Home
- THQ vs LENZ Comparison
THQ vs LENZ Comparison
Compare THQ & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- LENZ
- Stock Information
- Founded
- THQ 2014
- LENZ 2019
- Country
- THQ United States
- LENZ United States
- Employees
- THQ N/A
- LENZ N/A
- Industry
- THQ Finance Companies
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- THQ Finance
- LENZ Health Care
- Exchange
- THQ Nasdaq
- LENZ Nasdaq
- Market Cap
- THQ 782.9M
- LENZ 819.1M
- IPO Year
- THQ N/A
- LENZ 2021
- Fundamental
- Price
- THQ $18.33
- LENZ $29.16
- Analyst Decision
- THQ
- LENZ Strong Buy
- Analyst Count
- THQ 0
- LENZ 5
- Target Price
- THQ N/A
- LENZ $41.80
- AVG Volume (30 Days)
- THQ 158.9K
- LENZ 180.2K
- Earning Date
- THQ 01-01-0001
- LENZ 05-07-2025
- Dividend Yield
- THQ 7.53%
- LENZ N/A
- EPS Growth
- THQ N/A
- LENZ N/A
- EPS
- THQ N/A
- LENZ N/A
- Revenue
- THQ N/A
- LENZ N/A
- Revenue This Year
- THQ N/A
- LENZ N/A
- Revenue Next Year
- THQ N/A
- LENZ $534.98
- P/E Ratio
- THQ N/A
- LENZ N/A
- Revenue Growth
- THQ N/A
- LENZ N/A
- 52 Week Low
- THQ $15.29
- LENZ $14.42
- 52 Week High
- THQ $20.38
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- THQ 47.94
- LENZ 57.21
- Support Level
- THQ $17.82
- LENZ $28.14
- Resistance Level
- THQ $18.73
- LENZ $30.09
- Average True Range (ATR)
- THQ 0.34
- LENZ 1.51
- MACD
- THQ 0.05
- LENZ 0.01
- Stochastic Oscillator
- THQ 55.86
- LENZ 76.97
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
Tekla Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies in the healthcare industry (including equity securities, debt securities, and pooled investment vehicles). The fund invests in securities of public and private companies.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.